[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100403070":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":95,"collaborators":98,"id":106,"slug":107,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":108,"sex":114,"minAge":115,"maxAge":10,"enrollmentInfo":116,"targetDuration":119,"studyType":120,"phases":10,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Shanghai 10th People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Low burden of new-onset atrial fibrillation",null,"Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization. Among this subset of patients, those who have a NOAF burden value\\\u003C10.87% (previously established) will be divided into the low burden group.",[13],"Device: Continuous Electronic Monitor",{"label":15,"type":10,"description":16,"interventionNames":17},"High burden of new-onset atrial fibrillation","For patients with NOAF complicating AMI, those who have a NOAF burden value≥10.87% (previously established) will be divided into the high burden group.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DEVICE","Continuous Electronic Monitor","All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden",[15,9],[25],{"name":26,"affiliation":27,"role":28},"Yidong Wei, M.D., Ph.D.","Department of Cardiology, Shanghai Tenth People's Hospital","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Jiachen Luo, M.D., Ph.D.","CONTACT","+86-188-0179-0469","messichen@tongji.edu.cn",[36,52,64,75,87],{"facility":37,"status":38,"city":39,"state":40,"zip":10,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Kaifeng Central Hospital","RECRUITING","Kaifeng","Henan","China","CN",{"type":44,"coordinates":45},"Point",[46,47],114.30742,34.7986,{"lat":47,"lon":46},[50],{"name":51,"role":28,"phone":10,"phoneExt":10,"email":10},"Lei Qin, M.D.",{"facility":53,"status":38,"city":54,"state":40,"zip":10,"country":41,"countryCode":42,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Luoyang Central Hospital","Luoyang",{"type":44,"coordinates":56},[57,58],112.43684,34.67345,{"lat":58,"lon":57},[61,63],{"name":62,"role":32,"phone":10,"phoneExt":10,"email":10},"Xuewei Chang, M.D., Ph.D.",{"name":62,"role":28,"phone":10,"phoneExt":10,"email":10},{"facility":65,"status":38,"city":66,"state":40,"zip":10,"country":41,"countryCode":42,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou",{"type":44,"coordinates":68},[69,70],113.64861,34.75778,{"lat":70,"lon":69},[73],{"name":74,"role":32,"phone":10,"phoneExt":10,"email":10},"Hongqiang Li, M.D., Ph.D.",{"facility":27,"status":38,"city":76,"state":77,"zip":78,"country":41,"countryCode":42,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Shanghai","Shanghai Municipality","200072",{"type":44,"coordinates":80},[81,82],121.45806,31.22222,{"lat":82,"lon":81},[85,86],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},{"name":26,"role":28,"phone":10,"phoneExt":10,"email":10},{"facility":88,"status":38,"city":76,"state":77,"zip":10,"country":41,"countryCode":42,"cosmosGeoPoint":89,"geoPoint":91,"contacts":92},"Shanghai Seventh People's Hospital",{"type":44,"coordinates":90},[81,82],{"lat":82,"lon":81},[93],{"name":94,"role":28,"phone":10,"phoneExt":10,"email":10},"Shaowei Zhuang, M.D.",{"type":28,"investigatorFullName":96,"investigatorTitle":97,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ya-Wei Xu","Chief Physician",[99,101,102,104,105],{"name":100,"class":6},"Shanghai Tong Ren Hospital",{"name":37,"class":6},{"name":103,"class":6},"Shanghai 7th People's Hospital",{"name":65,"class":6},{"name":53,"class":6},"100403070","burden-of-new-onset-atrial-fibrillation-in-patients-with-acute-myocardial-infarction-100403070",false,"NCT04528511","BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction","BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction: the BENEFIT-AMI Multicenter Prospective Registry","BENEFIT-AMI","Inclusion Criteria:\n\n* Adult patients (\\>18 years old);\n* Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization;\n* Patients must have received in-hospital CEM for at least 5 days;\n* Patients must give informed consent.\n\nExclusion Criteria:\n\n* Patients with a medical history of pre-existing AF;\n* Patients with a medical history of rheumatic valvular disease;\n* Patients with a medical history of sick sinus syndrome;\n* Patients undergoing emergent coronary artery bypass surgery;\n* Patients who suffer malignant tumors with an expected lifetime less than 1 year ;\n* Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved;\n* Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI;\n* Patients who have died during the index hospitalization.","ALL","18 Years",{"count":117,"type":118},774,"ESTIMATED","2 Years","OBSERVATIONAL","To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.",[123,124],"Atrial Fibrillation New Onset","Acute Myocardial Infarction",[124,126,127,128,129],"New-Onset Atrial Fibrillation","Burden","Prospective","Cardiovascular Outcomes","2026-03-16",{"date":132,"type":133},"2026-03-19","ACTUAL",{"date":135,"type":133},"2020-10-01",{"date":137,"type":118},"2028-06-30",{"name":5,"class":6},5]